Revenue Disclosure by Business Area and Timing of Revenue Transfer
First written in FY2024-Q3. . Latest entry: FY2026.
41 other companies' latest entry also says "Other".
- FY2026Full-year update to revenue by business area and service lineAnnual report
「Safety and other areas 1,499,123 102.1 / Product sales 1,209,942 111.9 / Contract testing services 355,590 77.3」
Full-year revenue was ¥1,499.123 million in the safety and other areas, ¥1,209.942 million from product sales and ¥355.590 million from contract testing services, with the safety and other areas and product sales as the main contributors. - FY2026-H1Interim update to revenue by business area and timing of revenue transferAnnual report
「Current interim consolidated fiscal period (1 April 2025 to 30 September 2025) Pharmacology and drug efficacy Safety and other areas Total Goods transferred at a point in time 18,177 605,092 623,270 Services transferred over time 13,142 119,939 133,082 Revenue from contracts with customers 31,320 725,031 756,352」
Revenue from contracts with customers during the interim period was ¥31.320 million in the pharmacology and drug efficacy area and ¥725.031 million in the safety and other areas. The latter accounted for most of the total, while the former declined from ¥67.126 million in the same period of the previous year. - FY2025Full-year update to revenue by business area and service lineAnnual report
「Pharmacology and drug efficacy 73,138 45.9 / Safety and other areas 1,468,249 94.4 / Product sales 1,081,470 81.9 / Contract testing services 459,918 116.3」
Full-year revenue was updated by business area and service line. The safety and other areas, at ¥1,468.249 million, and product sales, at ¥1,081.470 million, were the main contributors, while the pharmacology and drug efficacy area declined to ¥73.138 million. - FY2025-H1Interim update to revenue by business area and timing of revenue transferAnnual report
「Current interim consolidated fiscal period (1 April 2024 to 30 September 2024) Pharmacology and drug efficacy Safety and other areas Total Goods transferred at a point in time 46,711 648,888 695,600 Services transferred over time 20,414 72,186 92,601 Revenue from contracts with customers 67,126 721,075 788,201」
Revenue from contracts with customers during the interim period was ¥67.126 million in the pharmacology and drug efficacy area and ¥721.075 million in the safety and other areas, with the latter accounting for most of the total. - FY2024-Q3First statedAnnual report
「Cumulative third-quarter period of the current consolidated fiscal year (1 April 2023 to 31 December 2023) Pharmacology and drug efficacy Safety and other areas Total Goods transferred at a point in time 67,515 1,050,582 1,118,098 Services transferred over time 85,359 125,172 210,532 Revenue from contracts with customers 152,875 1,175,755 1,328,631 Other revenue － － － Revenue from external customers 152,875 1,175,755 1,328,631」
In its revenue recognition disclosures, the company reports revenue from the pharmacology and drug efficacy and safety and other areas by whether it is transferred at a point in time or over time. Revenue from external customers in the safety and other areas was ¥1,175.755 million, accounting for most of the total of ¥1,328.631 million.